Hot on the heels of the name change of its subsidiary from Fuji Xerox to Fujifilm Business Innovation Corp., FUJIFILM Holdings Corporation is establishing new organisations for the Healthcare, Imaging and Graphic fields, to accelerate the generation of further synergies and new businesses in each sector.
Incoming Chairman Kenji Sukeno replaces iconic leader Shigetaka Komori who is credited with enabling Fujifilm to survive and prosper while major photo-chemical rivals such as Kodak and Agfa struggled. Komori, 82, will remain as Chief Advisorto both Fujifilm Holdings and Fujifilm Corporation. Teiichi Goto moves up to become President and CEO, Representative Director of both companies.
 |
| Komori (L) remains as Chief Advisor, Sukeno (R) becomes Chairman and CEO |
Graphic Systems division
From July 1st 2021, in order to accelerate the creation of group-wide synergy and offer even greater values to the printing industry globally, Fujifilm’s Graphic Systems Business Division and Fujifilm Business Innovation - known as Fuji Xerox prior to April 1st - and Graphic Communication Services Business Group, will be integrated into the Graphic Communication Business Division.
Fujifilm’s Graphic Systems business, which boasts far-reaching customer base primarily in commercial printing and packaging printing, will be combined with the marketing, technological and product strengths of Fujifilm Business Innovation’s Production business, whose strength lies in digital printing technology. The integration allows Fujifilm to deploy end-to-end solutions covering both analogue and digital printing, to become the industry’s driving force toward digitisation. This covers end-to-end delivery of production printers based on Fujifilm Business Innovation’s xerography technology, as well as Fujifilm’s Jet Press series of inkjet digital press, wide-format inkjet printers, digital presses for the packaging market, printing tools and materials.
The need for images and videos from society and daily life are diversifying amidst rapid advancement in various technologies, as seen in the diversification of image-recording devices such as smartphones, introduction of high-speed 5G network, advancement in AI technology and progress toward data-oriented society. Fujifilm is redefining the market from broader perspectives in integrating the two business divisions to accelerate the development of new products and services based on its brand power as a comprehensive photo imaging company as well as technological assets that cover fields ranging from imaging devices to photo printing systems and services.
Healthcare
Reorganisation will take place to further accelerate the expansion of the healthcare business, a growth driver of Fujifilm. This involves a division into the Medical System, mainly consisting of medical devices for diagnoses, and the Life Sciences, covering businesses such as Bio CDMO and drug development support. The Life Sciences Strategy Headquarters will be newly-established to lead the businesses for the Life Sciences.
The Life Sciences Strategy Headquarters will plan and promote a comprehensive, integrated strategy including business portfolio management, M&A, alliances and R&D, to generate further synergies and new businesses within its business field. In addition to the Bio CDMO Division and the Pharmaceutical Products Division, the Life Sciences Business Division will be newly established to enhance business for drug development support, by integrating the iPS cell, cell culture media and reagent businesses, which are currently separated in the Regenerative Medicine Business Division and the Fine Chemical Business Division. The current Life Science Products Division, handling cosmetics and supplements, will be renamed to the Consumer Healthcare Business Division.
Fujifilm Healthcare is already deeply involved in fighting Covid-19, with rapid testing kits and a manufacturing facility in northern England that will make the Novavax vaccine, of which Austrlia has ordered 51 million doses for delivery in the second half of 2021, subject to successful Stage III trials.
